SCHEMBL9500293

SCHEMBL9500293

N=C(N)c1ccc(O)c(Cl)c1

nearest known ligand 0.50

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
LMNA P02545 3/20 0.50
CA1 P00915 1/20 0.50
CA2 P00918 1/20 0.50
F12 P00748 1/20 0.48
TSHR P16473 1/20 0.48
HSD17B10 Q99714 1/20 0.48
PRSS1 P07477 3/20 0.47
PRSS3 P35030 2/20 0.47
PRSS2 P07478 1/20 0.47
F2 P00734 4/20 0.46
F10 P00742 2/20 0.46
PLAU P00749 3/20 0.45
PLG P00747 1/20 0.45
KLKB1 P03952 1/20 0.45
KLK1 P06870 1/20 0.45
HSP90AA1 P07900 1/20 0.44
HSP90AB1 P08238 1/20 0.44
SMN1; SMN2 Q16637 1/20 0.44
MASP2 O00187 1/20 0.43
THPO P40225 1/20 0.43

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL7323561 0.88 F10 (0.44) LMNACA1CA2F12TSHR
Trifluoroacetic Acid SCHEMBL13269478 0.85 KLK1 (0.50) LMNACA1CA2F12TSHR
SCHEMBL27242081 0.83 LMNA (0.50) LMNAF12TSHRHSD17B10PRSS1
SCHEMBL10436207 0.82 LMNA (0.54) LMNAF12TSHRPRSS1PRSS3
Hydrochloric Acid SCHEMBL11798099 0.80 LMNA (0.58) LMNAF12TSHRPRSS1PRSS3
SCHEMBL17134224 0.80 CA2 (0.52) LMNACA1CA2TSHRHSD17B10
SCHEMBL9314470 0.79 LMNA (0.54) LMNACA1CA2F12HSD17B10
SCHEMBL1786932 0.78 LCK (0.53) LMNACA1CA2TSHRHSD17B10
SCHEMBL30765123 0.78 LCK (0.53) LMNACA1CA2TSHRHSD17B10
SCHEMBL19523347 0.78 SMN1; SMN2 (0.53) LMNACA1CA2TSHRHSD17B10

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 23 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20150313889-A1 HETEROARYLCARBOXYLIC ACID ESTER DERIVATIVE AJINOMOTO CO., INC. (JP) 2015-11-05 US disclosed
US-20150313889-A1 HETEROARYLCARBOXYLIC ACID ESTER DERIVATIVE AJINOMOTO CO., INC. (JP) 2015-11-05 US disclosed
US-9115107-B2 Heteroarylcarboxylic acid ester derivative AJINOMOTO CO., INC. (JP) 2015-08-25 US disclosed
US-9115107-B2 Heteroarylcarboxylic acid ester derivative AJINOMOTO CO., INC. (JP) 2015-08-25 US disclosed
US-20150011511-A1 HETEROARYLCARBOXYLIC ACID ESTER DERIVATIVE AJINOMOTO CO., INC. (JP) 2015-01-08 US disclosed
US-20150011511-A1 HETEROARYLCARBOXYLIC ACID ESTER DERIVATIVE AJINOMOTO CO., INC. (JP) 2015-01-08 US disclosed
US-8877805-B2 Heteroarylcarboxylic acid ester derivative AJINOMOTO CO., INC. (JP) 2014-11-04 US disclosed
US-8877805-B2 Heteroarylcarboxylic acid ester derivative AJINOMOTO CO., INC. (JP) 2014-11-04 US disclosed
US-20140080790-A1 HETEROARYLCARBOXYLIC ACID ESTER DERIVATIVE AJINOMOTO CO., INC. (JP) 2014-03-20 US disclosed
US-20140080790-A1 HETEROARYLCARBOXYLIC ACID ESTER DERIVATIVE AJINOMOTO CO., INC. (JP) 2014-03-20 US disclosed
EP-0535037-A1 HYBRID PLASMINOGEN ACTIVATORS BEECHAM GROUP PLC (GB) 1993-04-07 EP disclosed
WO-1991019793-A2 HYBRID PLASMINOGEN ACTIVATORS BEECHAM GROUP PLC (GB) 1991-12-26 WO disclosed
EP-0283563-B1 NOVEL DERIVATIVES BEECHAM GROUP PLC (GB) 1991-05-29 EP disclosed
EP-0155388-B1 ENZYME-PROTEIN CONJUGATE, PROCESS FOR ITS PREPARATION AND PHARMACEUTICAL USE THEREOF BEECHAM GROUP PLC (GB) 1989-03-29 EP disclosed
EP-0283563-A2 Novel derivatives BEECHAM GROUP PLC (GB) 1988-09-28 EP disclosed
US-4741903-A Novel enzyne derivatives BEECHAM GROUP P.L.C. (GB) 1988-05-03 US disclosed
US-4730050-A Novel enzyme derivatives BEECHAM GROUP P.L.C. (GB) 1988-03-08 US disclosed
US-4600580-A Novel enzyme derivatives BEECHAM GROUP P.L.C. (GB) 1986-07-15 US disclosed
EP-0184363-A2 Enzyme conjugates and their therapeutical use BEECHAM GROUP PLC (GB) 1986-06-11 EP disclosed
EP-0155388-A2 Enzyme-protein conjugate, process for its preparation and pharmaceutical use thereof BEECHAM GROUP PLC (GB) 1985-09-25 EP disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20140080790-A1 HETEROARYLCARBOXYLIC ACID ESTER DERIVATIVE DPP4, DPP9, DPP7 LMNA 2175/4885CA1 1650/4885CA2 1208/4885
US-20150011511-A1 HETEROARYLCARBOXYLIC ACID ESTER DERIVATIVE DPP4, DPP9, DPP7 LMNA 2175/4885CA1 1650/4885CA2 1208/4885
US-20150313889-A1 HETEROARYLCARBOXYLIC ACID ESTER DERIVATIVE DPP4, DPP9, DPP7 LMNA 2175/4885CA1 1650/4885CA2 1208/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.